Intrahepatic cholestatic syndromes: Pathogenesis, clinical features and management

Digestive Diseases

Volumn 17, Issue 1, 1999, Pages 49-59

  Qureshi, Waqar A ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Gastrointestinal Medical Oncology   (United States)

Author keywords

Cholestasis; Drug induced cholestasis; Graft versus host disease; Pathogenesis, cholestasis; Pregnancy related cholestasis; Ursodeoxycholic acid

Indexed keywords

ATENOLOL; AZATHIOPRINE; CAPTOPRIL; CHLORPROPAMIDE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN A; DANAZOL; ENZYME INDUCING AGENT; ERYTHROMYCIN; ESTROGEN; FLOXURIDINE; FLURAZEPAM; GRISEOFULVIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIPRAMINE; NALOXONE; ONDANSETRON; OPIATE ANTAGONIST; PHENOBARBITAL; PROPOFOL; RESIN; RIFAMPICIN; S ADENOSYLMETHIONINE; SEROTONIN 3 ANTAGONIST; TERFENADINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID;

CLINICAL FEATURE; DROWSINESS; HEMOPERFUSION; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER TOXICITY; LIVER TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; REVIEW;

CHOLESTASIS, INTRAHEPATIC; HUMANS; SYNDROME;

EID: 0032806827     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016903     Document Type: Review

References (60)

1. Desmet VJ: Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998;73:80-89.
2. Azer SA, Stacey NH: Current concepts of hepatic uptake, intracellular transport and biliary secretion of bile acids: Physiological basis and pathophysiological changes in cholestatic liver dysfunction. J Gastroenterol Hepatol 1996;11: 396-407.
3. Sellinger M, Boyer JL: Physiology of bile secretion and cholestasis; in Popper H. Schaffner F (eds): Progress in Liver Diseases, vol 9. Philadelphia, Saunders, 1990. pp 237-259.
4. Zimniak P, Radominska A, Lester R: The pathogenesis of cholestasis. Hosp Pract 1990;25: 107-125.
5. Suchy FJ: Liver Disease in Children. St Louis, Mosby. 1994.
6. Zakim D, Boyer TD: Hepatology. A Textbook of Liver Disease, ed 3. Philadelphia, Saunders, 1996, pp 1649-1698.
7. Alagille D: Alagille syndrome today. Clin Invest Med 1996;19:325-330.
8. Akerboom T, Schneider I, vom Dahl S, Sies H: Cholestasis and changes of portal pressure caused by chlorpromazine in the perfused rat liver. Hepatology 1991;13:216-221.
9. Simon FR, Fortune J, Iwahashi M, Gartung C. Wolkoff A, Sutherland F: Ethinyl estradiol cholestasis involves alterations in expression of liver sinusoidal transporters. Am J Physiol 1996; 271:G1043-G1052.
10. Landman L: Cholestasis-induced alterations of the trans- and paracellular pathways in rat hepatocyles. Histoehem Cell Biol 1995;103:3-9.
11. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, Das K: Acute liver disease associated with erythromycins, sulfonamides and tetracyclines. Ann Intern Med 1993;119:576.
12. Erlinger S: Drug-induced cholestasis. J Hepatol 1997;26(suppl 1):1-4.
13. Perez Moreno JM, Saldana Gonzalez FJ, Puertas Monenegro M, Baez Perea J: Cholestatic hepatitis caused by midecamycin (in Spanish). Gastroenterol Hepatol 1996;19:459-461.
14. Fleming CR: Hepatobiliary complications in adults receiving nutrition support. Dig Dis 1994;12:191-198.
15. Moss RL, Das JB, Raffensperger JG: Total parenteral nutrition-associated cholestasis: Clinical and histopathologic correlation. J Pediatr Surg 1993;28:1270-1275.
16. Moss RL, Das JB, Ansari G, Raffensperger JG: Hepatobiliary dysfunction during total parenteral nutrition is caused by infusate, not the route of administration. J Pediatr Surg 1993;28: 391-396.
17. Moseley RH: Sepsis associated cholestasis. Gastroenterology 1997;112:302-306.
18. Bolder U, Ton-Nu HT, Schteingart CD, et al: Hepatocyte transport of bile acids and organic anions in endotoxemic rats: Impaired uptake and secretion. Gastroenterology 1997;112:214-225.
19. Reynolds MA, Siow Y, Collet D, Klar E, Richardson JD, Vitale GC: The role of bile acid secretion in response to operation and infection. Am Sure 1995;61:469-474.
20. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, Fraser DW: Toxicshock syndrome in menstruating women: Association wilh tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980;303:1436.
21. Brites D, Poeiras J, Rodrigues C: Intrahepatic cholestasis in pregnancy. Its etiopathogenesis, prognosis and therapy (in Portugese). Acta Med Port 1994;7:181-188.
22. Reyes H: Review: Intrahepatic cholestasis. A puzzling disorder of pregnancy. J Gastroenterol Hepatol 1997;12:211-216.
23. Bijeveld CMA, Vonk RH, Kuipers F, Havinga R, Boverhof R, Koopman BJ, Wolthers BG, Fernandes J: Benign recurrent intrahepatic cholestasis: Altered bile acid metabolism. Gastroenterology 1989;97:427-432.
24. Nakamuta M, Sakamoto S, Miyata Y, Sato M, Nawata H: Benign recurrent intrahepatic cholestasis: A long-term follow-up. Hepatogastroenterology 1904;41:287-289.
25. Reynods MA, Siow Y, Collet D, Klar E, Richardson JD, Vitale GC: The role of bile acid secretion in the hepatic response to operation and infection. Am Surg 1995;61:469-474.
26. Gordon SC, Reddy KR, Schiff L, Schiff ER: Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984;101: 635.
27. Chapman RW: Role of immune factors in the pathogenesis of primary sclerosing cholangitis. Semin Liver Dis 1991;11:4.
28. Vierling JM, Hu K-Q: Immunologic mechanisms of hepatobiliary injury: in Kaplowitz N (ed): Liver and Biliary Diseases. Baltimore. Williams & Wilkins, 1992, pp 48-69.
29. Fausa O, Schrumpf E, Elgio K: Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11: 31-39.
30. Vierling JM: Hepatobiliary complications of ulcerative colitis and Crohn's disease: in Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease. Philadelphia, Saunders, 1990, pp 1126-1157.
31. Snover DC, Weisdorf SA, Ramsay NK, McGlave P, Kersey JH: Graft versus host disease: A study of the predictive value of liver biopsy in diagnoses. Hepatology 1984;4:123-130.
32. Friedrh RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB: Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992;116:624-629.
33. Erlinger S: Hypercholeretic bile acids: A clue to the mechanism? Hepatology 1990;11:888-890.
34. Myers NC, Grune S, Jameson HL, Sawkat-Anwer M: cGMP stimulates bile acid-independent bile formation and biliary bicarbonate excretion. Am J Physiol 1996;270:G418-G424.
35. Burgart LJ: Cholangitis in viral disease. Mayo Clin Proc 1998;73:479-482.
36. Martelius T, Krogerus L, Hockerstedt K, Bruggeman C, Lautenschlager L: Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 1998;27:996-1002.
37. Cello JP: Acquired immunodeficiency syndrome cholangiography: Spectrum of disease. Am J Med 1989;86:536-546.
38. Slitzky BE, Ouellette GS, Boyer JL: Approaches to the treatment of primary biliary cirrhosis - A status report. Gastroenterol Int 1990;3:134-139.
39. Lindor KD, Wiesner RH, MacCarty RL, Ludwig J, LaRusso NF: Advances in primary sclerosing cholangitis. Am J Med 1990;89:73-80.
40. Berg CL, Gollan JL: Primary biliary cirrhosis: New therapeutic directions. Scand J Gastroenterol 1992;37(suppl 192):43-49.
41. Reichen J: Pharmacologic treatment of cholestasis. Semin Liver Dis 1993;13:302-315.
42. Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, Bircher J, Folsch U, Klaus J, Endele R: Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990;12:492-497.
43. Lindor KD, Lacerda MA, Jorgensen RA, DeSotel CK, Batta AK, Salen G, Dickson ER, Rossi SS, Hofmann AF: Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol 1998;93: 1498-1504.
44. Calmus Y, Gane P, Rouger P, Poupon R: Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990;22:12-15.
45. Beuers U. Thiel M, Bardenheuer H, Paumgartner G: Tauroursodeoxycholic acid inhibits the cytosolic calcium increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine. Biochem Biophys Res Commun 1992;171:1115-1121.
46. Takikawa H, Sano N, Minagawa K, Yamanaka M: Etfects of ursodeoxycholate, its glucoronide and disullate and beta-muricholate on biliary bicarbonate concentration and biliary lipid excretion. J Hepatol 1992;15:77-84.
47. Poupon RE, Balkau B, Eschwige E, Igglesias J, Gonzaliz MC, Hernandez I, Alvarec C, Molina C, Danitz AM: A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
48. O'Brien CB, Senior JR, Arora-Michandani R, Batta AK, Salen G: Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study. Hepatology 1991;14: 838-847.
49. Palma J, Reyes H, Ribalta J, Gonzalez MC, Hernandez I, Alvarez C, Molina C, Danitz AM: Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology 1992;15:1043-1047.
50. Brites D, Rodregues CM, Oliveira N, Cardoso M, Graca LM: Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998;28:91-98.
51. Wictholtz H, Marschall HU, Sjovall J, Matern S: Stimulation of bile acid 6-alpha-hydroxylation by rifampicin. J Hepatol 1996;24:713-781.
52. Osman E, Owens JS, Burroughs AK: Review article. S-Adenosyl-L-methionine: A new therapeutic agent in liver disease? Aliment Pharmacol Ther 1993;7:21-28.
53. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C: Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: A double-blind, placebo-controlled study. Gastroenterology 1990;99: 211-215.
54. Bargasa NV, Talbot TC, Alling DW, Schmitt JM, Walker EC, Baker BL, Koreman JC, Park Y, Hoofnagle JH, Jones EA: A controlled trial of nalaxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-549.
55. Borgeat A, Wilder-Smith OH, Mentha G: Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993;104:244-247.
56. Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Radever M, Scheithaver W. Ferenci P: Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo-controlled, double-blind, cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-870.
57. Alarabi AA, Wikstrom B, Loof L, Danielson BG: Treatment of pruritus in cholestatic jaundice by bilirubin and bile acid-adsorbing resin column plasma perfusion. Scand J Gastroenterol 1992;27:223-226.
58. Omokawa S, Yamashita M, Malchesky PS, Koo AP, Matsushita M, Nose Y: Therapeutic plasmapheresis for cholestatic liver diseases: Study of 9 cases. Prog Clin Biol Res 1990;337:233-236.
59. Rosenthal E, Diamond E, Benderly A, Etzioni A: Cholestatic pruritus: Effect of phototherapy on pruritus and excretion of bile acids in urine. Acta Paediatr 1994;83:888-891.
60. Khandelwal M, Malet PF: Pruritus associated with cholestasis. A review of pathogenesis and management. Dig Dis Sci 1994;39:1-8.